2020-01-012024-05-17https://scholars.lib.ntu.edu.tw/handle/123456789/673130摘要：血液是在人體內全身循環流動的組織液體，當人體產生任何生理變化或是罹患疾病時，血液中的成分如血球個數、蛋白質、抗體、激素等都可能產生變化，因此血液成分檢測能提供許多人體重要且即時的資訊。然而傳統的血液檢測往往需要仰賴醫院中的專業操作人員，此外檢測時間亦需要數日以上，因此對於無法即時且有效地提供醫生所需診斷資訊或是長時間的生理參數監測。為解決上述問題，本計劃希望能開發可進行快速全血處理及生物標記物感測之微流道系統，可直接在微型晶片上進行血液樣本處理及其中成分的分析檢測。為達到血液處理的部份，本計劃將搭配數種物理性或化學性的血液處理機制，如血球濾膜、血液沉降槽、血球聚集化合物等方式，將上述機制合併使用整合於微流道晶片中，使血球處理過程更迅速和高純度。和傳統血液檢測方式相比，可大幅度減少所需血液樣本量。此外為使簡化整理操作步驟，讓未受過專業訓練的使用者也能進行，本計劃將導入微流道控制系統，包含微型幫浦、閥門、儲存槽、廢液槽等設計，使整體操作流程更為簡單和人性化。最後，本計劃將整合電子感測晶片於全血處理微流道晶片中，目標為在血液樣本一處理完後，就直接對有興趣的生物標記物進行感測，如此可避免樣本可能的污染、耗損及人為操作的誤差。為達到將來商用化的目的，我們將會選擇可量產化的材料及製程進行系統的開發，希望此系統未來可廣泛的作為遠端醫療等定點照護之應用，降低病患前往醫院就醫所需之醫療成本。<br> Abstract: Blood is composed of plasma, red blood cells (RBCs), white blood cells (WBCs), and platelets, and it contains numerous types of physiological and pathological information about the human body. To understand patients’ health status, complete blood count (CBC) tests, as one of the most common blood tests, shows the count of each cell type, cell sizes, the fraction of specific cells in whole blood, and the concentration of various proteins, creatinine, or metabolites. Although very useful, CBC tests are usually only required the operation by well-trained technician in laboratories or hospitals, which limited the applications in publics. To address above problems, we propose a multi-functional microfluidic platform for rapid whole blood processing and simultaneous biomarkers detection. The system contains complete whole blood assay functions, including whole blood processing and biomarkers detection in a micro-size biochip. To enable efficient whole blood processing, we will investigate a suitable whole blood processing mechanism and integrate them inside the microfluidic channel. Then, we will design an automated microfluidic flow control system, including micro-pumps, micro-valves and reservoirs, to guide and switch different reagents into the system, which can prevent any potential sample contamination, loss and reduce the operational difficulties. Finally, we aim to introduce electrical-based microsensors into the microfluidic system to enable in-situ multiple biomarkers detection. To move toward to commercialization, we will carefully choose suitable materials and fabrication processes, which can potentially enable mass-production. In summary, we hope the proposed microfluidic platform could potentially be applied for blood analysis in resource-limited environments or point-of-care settings.微流道系統全血處理微感測器多生化分子感測Microfluidicswhole blood processingmicrosensormultiplex biosensing